Biocon's growth formula: Generics & biosimilars
Biocon is set for major growth in the next 2-3 years, propelled by new generics and biosimilars. The Viatris acquisition strengthens its position in the U.S. market, with significant market share in some products already achieved. December quarter revenue increased by 14% in biosimilars and research services.
Biocon is set for major growth in the next 2-3 years, propelled by new generics and biosimilars. The Viatris acquisition strengthens its position in the U.S. market, with significant market share in some products already achieved. December quarter revenue increased by 14% in biosimilars and research services. What's Your Reaction?
